Last reviewed · How we verify

Ileocolonic release peppermint oil

Maastricht University Medical Center · Phase 3 active Small molecule

Ileocolonic release peppermint oil delivers peppermint oil directly to the ileum and colon, where it exerts antispasmodic and anti-inflammatory effects on the lower gastrointestinal tract.

Ileocolonic release peppermint oil delivers peppermint oil directly to the ileum and colon, where it exerts antispasmodic and anti-inflammatory effects on the lower gastrointestinal tract. Used for Irritable bowel syndrome (IBS) with abdominal pain and cramping, Functional bowel disorder symptoms.

At a glance

Generic nameIleocolonic release peppermint oil
SponsorMaastricht University Medical Center
Drug classHerbal antispasmodic agent
ModalitySmall molecule
Therapeutic areaGastroenterology
PhasePhase 3

Mechanism of action

Peppermint oil contains menthol and other volatile compounds that act as calcium channel antagonists and smooth muscle relaxants. The ileocolonic release formulation uses enteric coating to protect the oil from gastric degradation, ensuring targeted delivery to the distal small intestine and colon where it can reduce visceral pain, bloating, and abnormal motility associated with functional bowel disorders.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results